Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR201920202021
Revenues<1m<1m<1m
% growth-686 %50 %
EBITDA(<1m)(<1m)(<1m)
% EBITDA margin(1444 %)(590 %)(1159 %)
Profit(<1m)(<1m)(<1m)
% profit margin(1444 %)(616 %)(1561 %)
  • Edit
DateInvestorsAmountRound

€70.0k

Grant

N/A

Spinout
*

€1.5m

Seed

€50.0k

Grant

€1.2m

Seed

€1.6m

Seed
N/A

N/A

-

€2.5m

Grant
*

€11.0m

Debt
*

€42.0m

Early VC
Total Funding€48.9m

Recent News about Arthex Biotech

Edit
More about Arthex Biotech
Edit

Developer of anti-microRNAs designed for the treatment of diseases with unmet needs. The company develops drugs and therapies that are designed to treat a variety of disorders in which microRNAs play a role, enabling medical professionals to get access to therapy that helps treat patients suffering from genetic diseases, rare diseases, and diseases with high medical needs.

Keywords: Pharmaceuticals and Biotechnology, Antisense Oligonucleotide, Antisense Oligonucleotide Therapy, Muscular Dystrophy, Neuromuscular Disease, Neuromuscular Disease Therapeutics, Neuromuscular Disease Treatment, Neuromuscular Therapy, Oligonucleotide Therapeutics, Oligonucleotide Therapy.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.